A study published in The Lancet reveals that the HPV vaccine, already known to prevent roughly 90% of cervical cancer cases, offers even stronger protection than previously understood. For women who received the shot in early adolescence, the risk of death from cervical cancer before turning 30 is effectively zero, according to researchers.
The investigation, funded by Cancer Research UK, is the first to examine the vaccine's direct impact on mortality rates. In England alone, the analysis estimates that approximately 200 cervical cancer deaths have been prevented so far through vaccination programs. The authors stress that these figures are far larger on a global scale.
Human papillomavirus, a widespread sexually transmitted infection spread through skin-to-skin contact, can cause abnormal cell growth in some individuals, leading to several forms of cancer years later. While the immune system often clears the virus, persistent infections pose serious risks. The new findings underscore the vaccine's life-saving potential.
Public health bodies are now amplifying calls for widespread immunization. The World Health Organization, aiming to eliminate cervical cancer worldwide, has been urging member countries to vaccinate as many young people as possible. The Lancet study provides concrete evidence that such programs are already saving lives.
Despite the compelling data, skeptics caution that the study's focus on early mortality—before age 30—may not fully capture long-term outcomes. Cervical cancer typically develops over decades, and some argue that longer follow-up is needed to confirm enduring protection against late-stage deaths.